Gene · 81607
NECTIN4: nectin cell adhesion molecule 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NECTIN4: nectin cell adhesion molecule 4. Genes, record 81607. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/81607
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q96NY8 | Nectin-4 | 510 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents249
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4808978 A1 | 2026-09-23 | 25 | Q96NY8 | Espacenet |
| EP 4780498 A1 | 2026-07-29 | 2 | Q96NY8 | Espacenet |
| EP 4731673 A1 | 2026-04-29 | 1 | Q96NY8 | Espacenet |
| EP 4725964 A1 | 2026-04-15 | 31 | Q96NY8 | Espacenet |
| JP 2026048848 A | 2026-03-17 | 2 | Q96NY8 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58301 | Q96NY8 | Espacenet |
| JP 2025539087 A | 2025-12-03 | 71 | Q96NY8 | Espacenet |
| JP 2025539087 A | 2025-12-03 | 72 | Q96NY8 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8346 | Q96NY8 | Espacenet |
| JP 2025170007 A | 2025-11-14 | 2 | Q96NY8 | Espacenet |
1 to 10 of 249
See all 249 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| ENFORTUMAB VEDOTIN | CHEMBL3301589 | Nectin-4 binding agent | BINDING AGENT |
Source ChEMBL
Trials48
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07566156 | ENFORTUMAB VEDOTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07374549 | ENFORTUMAB VEDOTIN | PHASE2 | ClinicalTrials.gov | |
| NCT07347314 | ENFORTUMAB VEDOTIN | PHASE2 | ClinicalTrials.gov | |
| NCT07346053 | ENFORTUMAB VEDOTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07287995 | ENFORTUMAB VEDOTIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07232602 | ENFORTUMAB VEDOTIN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07221942 | ENFORTUMAB VEDOTIN | PHASE2 | ClinicalTrials.gov | |
| NCT07218380 | ENFORTUMAB VEDOTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07217496 | ENFORTUMAB VEDOTIN | PHASE1 | ClinicalTrials.gov | |
| NCT07183319 | ENFORTUMAB VEDOTIN | PHASE2 | ClinicalTrials.gov |
1 to 10 of 48
See all 48 trialsNIH grants580
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NECTIN4 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 29 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 12 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 11 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 9 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 5 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 4 | 2025 |
| P30DK054759 | Precision Medicine Center for Cystic Fibrosis | 4 | 2025 |
| P50CA116201 | Mayo Clinic Breast Cancer SPORE | 4 | 2025 |
| K12CA184746 | MSK Paul Calabresi Career Development Award for Clinical Oncology | 3 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 580Source NIH's project files
See all 580 nih grantsPapers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nectin-4-Directed Therapeutic Repositioning Augments Antitumor Efficacy in Epithelial Ovarian Carcinoma. | Cancer Commun (Lond) | 2026 | 42819105 | PubTator, text mining | PubMed |
| Nectin-4-Targeted PET/CT Before Organ-Sacrificing Surgery for Occult Ureteral Carcinoma. | J Nucl Med | 2026 | 42816126 | PubTator, text mining | PubMed |
| Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment. | Front Biosci (Landmark Ed) | 2026 | 42811988 | PubTator, text mining | PubMed |
| Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma. | Head Neck | 2026 | 42811719 | PubTator, text mining | PubMed |
| Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer. | Eur Urol | 2026 | 42786066 | PubTator, text mining | PubMed |
| NECTIN4, TROP2 and PDL1 in Breast Cancer: Immunohistochemical Profiling and Clinical Associations. | Int J Surg Pathol | 2026 | 42770457 | PubTator, text mining | PubMed |
| Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them. | Front Immunol | 2026 | 42769609 | PubTator, text mining | PubMed |
| Enfortumab vedotin-related cutaneous toxicity: Clinical features, pathogenesis and management. | J Dermatol Sci | 2026 | 42754439 | PubTator, text mining | PubMed |
| Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles. | Histopathology | 2026 | 42747234 | PubTator, text mining | PubMed |
| Expression of nectin-4 in squamous cell carcinoma of prostate: a pilot study and case report. | Front Oncol | 2026 | 42740991 | PubTator, text mining | PubMed |
1 to 10 of 1,879
See all 1,879 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/81607
GET https://conductscience.org/api/genes/v1/81607/patents?page=2